Bladder washing cytology in the initial evaluation of patients with neuro‐urological disorders: to do or not to do?
BJU International · 2026-11 · 138 (5) · 860-866
DOI: 10.1111/bju.70422 ↗Kurz gefasst
Fachartikel in der Zeitschrift BJU International, online erschienen am 16.08.2026. Verfasst von Fabienne Lehner und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuro-Urology, Balgrist University Hospital, University of Zürich, Zürich, Switzerland. Hauptthemen laut MEDLINE: Urinary Bladder, Urinary Bladder Neoplasms, Urinary Bladder, Neurogenic, Cytodiagnosis. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objectives
To evaluate if bladder washing cytology (BWC) provides a diagnostic benefit in the initial evaluation of patients with neuro‐urological disorders. Patients and Methods This prospective cross‐sectional study investigated a consecutive series of patients with lower urinary tract symptoms referred for neuro‐urological evaluation at our department of neuro‐urology who underwent urethro‐cystoscopy (UC) and BWC from 2018 to 2023.
Results
Among 581 neurological patients, 274 (47.2%) were females. Tumour‐suspicious findings leading to surgical intervention were detected in 17 (2.9%) by UC alone and in three (0.5%) by BWC but unsuspicious UC, respectively. Overall, relevant histological findings after transurethral bladder surgery (TUBS) were detected in eight (1.4%, 95% confidence interval [CI] 0.6–2.7%) patients: keratinising squamous metaplasia (two) and non‐muscle‐invasive urothelial carcinoma (six), all were initially identified by UC. Three patients refused surgery, two of whom had positive BWC without suspicious lesion in UC. Sensitivity and specificity of BWC referenced to UC alone were 0% (95% CI 0.0–36.9%) and 99.7% (95% CI 98.7–99.9%), respectively. Adding BWC to UC increased costs by 22.8% without improving tumour detection. The main study limitation was the lack of true positives in BWC.
Conclusions
Bladder washing cytology in addition to UC is not justified in the initial evaluation of patients with neuro‐urological disorders as decision making regarding TUBS is based on UC findings. Moreover, omission of BWC saves relevant costs without compromising patient safety.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neuro-Urology, Balgrist University Hospital, University of Zürich, Zürich, Switzerland.
- Spinal Cord Injury Center, Balgrist University Hospital, University of Zürich, Zürich, Switzerland.
- Swiss Paraplegic Research, Nottwil, Switzerland.
ORCID-Profile: Fabienne Lehner, Sarah Dugas, Veronika Birkhäuser, Oliver Gross, Lorenz Leitner, Ulrich Mehnert, Lara Stächele, Collene E Anderson, Thomas M Kessler
Zitieren
APA
Lehner, F., Dugas, S., Birkhäuser, V., Gross, O., Leitner, L., Mehnert, U., Stächele, L., Anderson, C. E., & Kessler, T. M. (2026). Bladder washing cytology in the initial evaluation of patients with neuro‐urological disorders: to do or not to do?. BJU International, 138(5), 860-866. https://doi.org/10.1111/bju.70422
Vancouver
Lehner F, Dugas S, Birkhäuser V, Gross O, Leitner L, Mehnert U, et al. Bladder washing cytology in the initial evaluation of patients with neuro‐urological disorders: to do or not to do?. BJU International. 2026;138(5):860-866. doi:10.1111/bju.70422
BibTeX
@article{Lehner2026,
author = {Lehner, Fabienne and Dugas, Sarah and Birkhäuser, Veronika and Gross, Oliver and Leitner, Lorenz and Mehnert, Ulrich and Stächele, Lara and Anderson, Collene E and Kessler, Thomas M},
title = {Bladder washing cytology in the initial evaluation of patients with neuro‐urological disorders: to do or not to do?},
journal = {BJU International},
year = {2026},
volume = {138},
number = {5},
pages = {860--866},
doi = {10.1111/bju.70422}
}
EUVIMED